A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis

Trial Profile

A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2015

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Intermediate uveitis; Posterior uveitis
  • Focus Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 16 Dec 2015 Planned end date changed from 1 Oct 2016 to 1 Oct 2018, as reported by ClinicalTrials.gov.
    • 16 Dec 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2018, as reported by ClinicalTrials.gov.
    • 16 Dec 2015 Planned initiation date changed from 1 Sep 2015 to 1 Jan 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top